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Introduction
G protein–coupled receptors (GPCRs) are the largest family 
of membrane proteins and mediate most cellular responses to 
neurotransmitters, peptide hormones, lipids, and sensory stim-
uli, as well as therapeutic drugs. The classical role of GPCRs 
is to couple the binding of ligands to the activation of specific 
heterotrimeric G proteins, leading to the regulation of down-
stream effector proteins. Signaling responses are attenuated by 
desensitization via a series of steps that uncouple GPCR from 
G proteins and lead to receptor internalization/down-regulation. 
However, this traditional view has been replaced by a much 
more complex signaling model. G protein–independent mech-
anisms and, more recently, signaling from endosomal compart-
ments have been described for several GPCRs (Rajagopal et al., 
2010; Lohse and Calebiro, 2013; Vilardaga et al., 2014).
Corticotropin-releasing hormone (CRH) is a 41-aa peptide 
that plays a critical role in the integration of neuroendocrine, 
autonomic, and behavioral responses to stress. Hypothalamic 
CRH-secreting neurons drive both basal and stress-induced 
activation of the hypothalamic-pituitary-adrenal (HPA) axis. 
In addition, CRH is widely distributed in the brain, where it 
functions as a neuromodulator, integrating a complex system 
that regulates several aspects of the behavioral stress response. 
Dysregulation of CRH action through its high-affinity type 1 
receptor (CRHR1) is crucial in the pathogenesis of affective 
disorders (Holsboer and Ising, 2010).
CRHR1 is a class B/secretin-like GPCR that, upon ligand 
activation, signals mainly by Gs coupling, leading to cyclic 
AMP (cAMP) increase and activation of multiple signaling 
cascades (Bonfiglio et al., 2011). In particular, CRH-stimulated 
CRHR1 signals through extracellular signal regulated kinase 
1/2 (ERK1/2) to induce proopiomelanocortin (Pomc) transcrip-
tion and activate the HPA axis in pituitary corticotrophs and in 
specific brain structures related to behavioral aspects of stress 
in response to intracerebroventricular CRH administration (Re-
fojo et al., 2005). We have previously described that in a hippo-
campal neuronal context, CRHR1-mediated ERK1/2 activation 
triggered by CRH is biphasic, with an early phase peaking at 
3–6 min that is dependent on B-Raf and protein kinase A (PKA) 
and a late phase of sustained ERK1/2 phosphorylation (20–60 
min) dependent on CRHR1 internalization and β-arrestin2 
(Bonfiglio et al., 2013).
Corticotropin-releasing hormone receptor 1 (CRHR1) activates G protein–dependent and internalization-dependent 
signaling mechanisms. Here, we report that the cyclic AMP (cAMP) response of CRHR1 in physiologically relevant sce-
narios engages separate cAMP sources, involving the atypical soluble adenylyl cyclase (sAC) in addition to transmem-
brane adenylyl cyclases (tmACs). cAMP produced by tmACs and sAC is required for the acute phase of extracellular 
signal regulated kinase 1/2 activation triggered by CRH-stimulated CRHR1, but only sAC activity is essential for the 
sustained internalization-dependent phase. Thus, different cAMP sources are involved in different signaling mechanisms. 
Examination of the cAMP response revealed that CRH-activated CRHR1 generates cAMP after endocytosis. Character-
izing CRHR1 signaling uncovered a specific link between CRH-activated CRHR1, sAC, and endosome-based signaling. 
We provide evidence of sAC being involved in an endocytosis-dependent cAMP response, strengthening the emerging 
model of GPCR signaling in which the cAMP response does not occur exclusively at the plasma membrane and introduc-
ing the notion of sAC as an alternative source of cAMP.
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The ubiquitous second messenger cAMP regulates nu-
merous, often concurrent, cellular processes. Its activity is 
tightly regulated and localized to discrete microdomains within 
the cell to ensure precise spatiotemporal signaling. GPCR- 
mediated cAMP production was initially thought to depend 
exclusively on activation of transmembrane adenylyl cyclases 
(tmACs) at the plasma membrane. More recently, a wealth of 
research has shown that some activated GPCRs continue to sig-
nal by cAMP generation after internalization, thereby defining 
endocytic cAMP microdomains (Vilardaga et al., 2014). There 
are nine G protein–regulated tmACs that have different regula-
tory properties (Willoughby and Cooper, 2007). Furthermore, a 
second source of cAMP exists in mammalian cells. Soluble ad-
enylyl cyclase (sAC) is an evolutionarily conserved enzyme that 
is insensitive to G protein regulation but is directly activated by 
bicarbonate (Chen et al., 2000) and calcium ions (Jaiswal and 
Conti, 2003; Litvin et al., 2003). sAC is localized throughout 
the cell, enabling the production of cAMP in different intra-
cellular locations close to specific cAMP targets (Zippin et al., 
2004; Tresguerres et al., 2011; Lefkimmiatis et al., 2013).
Combining molecular and pharmacologic tools with 
Förster resonance energy transfer (FRET)–based biosensor 
technology, we show that the CRHR1-triggered cAMP response 
does not exclusively depend on tmACs but also involves sAC as 
a second source of cAMP. Both cAMP sources play a role in the 
early ERK1/2 response, but only sAC activity is required for the 
late ERK1/2 activation phase. Our results indicate that CRH- 
activated CRHR1 generates cAMP from endocytic compart-
ments. By characterizing the CRHR1 signaling response, we 
show a functional association between sAC-generated cAMP, 
ERK1/2 activation, and endosome-based GPCR signaling.
Results
sAC contributes to CRHR1-triggered 
cAMP response in HT22-CRHR1 cells
It is now widely accepted that sAC, which was first identified 
in testis, is ubiquitously expressed (Tresguerres et al., 2011). 
RT-PCR results confirmed that sAC mRNA was present in total 
mouse brain and several mouse cell lines (Fig. 1 A), including 
HT22 cells stably expressing CRHR1 (HT22-CRHR1 cells). 
Using an anti-sAC monoclonal antibody (R21), a 48-kD protein 
was detected by Western blot in HT22-CRHR1 cells (Fig. S1 
A), and the immunoreactive band was reduced in cells trans-
fected with a sAC-specific siRNA (Fig. 1 B).
We used the FRET-based biosensor Epac-SH187, which 
localizes diffusely throughout the cytoplasm (Klarenbeek et 
al., 2015), to assess CRH-triggered cAMP production at the 
single-cell level in real time, without phosphodiesterase in-
hibitors. CRH stimulation of HT22-CRHR1 cells resulted in a 
rapid increase of intracellular cAMP levels that stayed elevated 
for at least 40 min after ligand bath application (Fig. S1 B). 
CRH addition produced a rapid decrease of acceptor emission 
(cp173Venus) and a corresponding increase in donor emission 
(mTurquoise2), confirming that the observed changes were 
caused by a FRET reduction, indicating a rise in cytoplasmic 
cAMP concentration (Fig. S1 B).
When the tmAC-selective inhibitor 2′,5′-dideoxyad-
enosine (ddA) was added during the time course, the cAMP 
response was inhibited (P < 0.001 with respect to control after 
5 min) but not completely blocked (Fig.  1  C). Interestingly, 
the sAC-specific inhibitor (Bitterman et al., 2013) 2-hydroxy- 
estradiol (2-HE) also significantly reduced cAMP levels (P 
< 0.01 with respect to control after 5 min; Fig. 1 C). We also 
determined cAMP content by means of competition with [3H]
cAMP for PKA in HT22-CRHR1 cells preincubated with ddA 
or sAC-specific inhibitor KH7 (Hess et al., 2005). Both inhibi-
tors significantly reduced the cAMP response triggered by CRH 
(Fig. S1 C). sAC contribution to the cAMP response triggered 
by CRH was also indicated by depleting cellular levels of en-
dogenous sAC (Fig. 1 E).
We tested whether isoproterenol, an agonist of β-adr-
energic receptors (which are also Gs coupled), triggered a 
sAC-dependent cAMP response. We observed that only the 
tmAC inhibitor significantly affected the cAMP increase elic-
ited by isoproterenol (Fig. 1 D; P < 0.001 with respect to con-
trol and 2-HE after 5 min), showing that sAC is not a general 
mediator of the cAMP response generated by GPCRs in the 
HT22 cellular context. Collectively, our data reveal that sAC 
is specifically involved in the CRHR1-mediated cAMP re-
sponse triggered by CRH.
We examined the blocking effect and the specificity of 
ddA and 2-HE on the cAMP response generated by tmACs and 
sAC. cAMP responses in cells stimulated with CRH or treated 
with the tmAC-specific activator forskolin were nearly iden-
tical in the presence of ddA (Fig. 1 F, top), reaching about a 
50% inhibition at the highest inhibitor concentration assayed 
(200 µM). 2-HE concentrations up to 40 µM had no effect on 
the cAMP response generated by forskolin but caused about a 
30% inhibition of the cAMP response to CRH (Fig. 1 F, bot-
tom). These results indicate that concentrations of 100  µM 
ddA and 20 µM 2-HE are sufficient to assess and discriminate 
the contribution of sAC- and tmACs-mediated processes with 
our experimental approach.
Do tmACs and sAC engage different 
biochemical cascades?
Multiple cAMP sources may contribute to a common cAMP 
pool, or they may act distinctly to elicit specific cellular re-
sponses. Having established that, in addition to tmACs, sAC is 
necessary for the CRH-activated CRHR1 cAMP response, we 
decided to evaluate whether specific cAMP sources have differ-
ent biological meanings in CRHR1 signaling. We investigated 
the role of both cAMP sources in ERK1/2 phosphorylation in 
HT22-CRHR1 cells. We have previously reported that ERK1/2 
can be activated via CRHR1 by both G protein–dependent and 
–independent mechanisms (Bonfiglio et al., 2013).
The dependence of ERK1/2 phosphorylation on different 
cAMP sources was first assessed using a pharmacologic ap-
proach (Fig. 2 A). As reported previously, specific inhibition of 
tmACs with ddA attenuated only the CRH-induced early (5 min) 
ERK1/2 activation phase (Bonfiglio et al., 2013). Two pharma-
cologic inhibitors of sAC, KH7 and 2-HE, reduced pERK1/2 
at the early and late time points (Figs. 2 A and S1 D). When 
both inhibitors were used in combination, a stronger reduction 
of pERK1/2 was observed at the early time point (Fig. 2 A). 
Furthermore, when the CRH-triggered cAMP response was 
analyzed with simultaneous addition of both AC inhibitors, a 
stronger inhibition was observed, further supporting the partici-
pation of both cAMP sources in the response (Fig. 2 B).
Next, we analyzed the time course of CRH-induced 
ERK1/2 phosphorylation after depleting endogenous sAC 
(Fig. 1 B). Knockdown of sAC significantly affected the early 
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but also the late phase of CRH-mediated pERK1/2 (Fig. 2 C). In 
HT22-CRHR1 cells, isoproterenol triggered a biphasic ERK1/2 
activation response similar to the one described in HEK293 
cells (Shenoy et al., 2006). However, sAC depletion did not 
affect ERK1/2 phosphorylation triggered by isoproterenol in 
these cells (Fig. 2 C), consistent with sAC not being involved 
in the cAMP response to isoproterenol in HT22-CRHR1 cells 
(Fig.  1  D). Interestingly, in these cells, CRH-induced neurite 
outgrowth was blocked by KH7, but ddA had no effect, show-
ing that the morphologic change requires sAC but not tmACs 
(Fig. 2 D). Together, these results show that tmACs and sAC 
can mediate different functions in CRH signaling.
sAC was identified in a search for B-Raf partners with a 
potential role in CRH signaling (Bonfiglio et al., 2013). B-Raf 
is the MAPK kinase kinase of the cascade leading to ERK1/2 
activation and also acts as a scaffold for assembling signaling 
complexes. Analysis of CRH-elicited signaling mechanisms re-
veals that whereas sAC contributes to the cAMP response to 
a small extent, it has a significant role in the phosphorylation 
of ERK1/2. Thus, the sAC-generated cAMP pool might be bi-
ased toward activation of the ERK1/2 pathway. Consistent with 
the fact that CRHR1 is a Gs-coupled GPCR, the classic signal 
transduction mechanism involves the generation of cAMP at 
the plasma membrane by G protein–regulated tmACs, which is 
apparent in the early phase of ERK1/2 activation (Bonfiglio et 
al., 2013). The effect of sAC inhibition or depletion on the late 
phase of pERK1/2 reveals the requirement of CRH-activated 
sAC in the sustained signaling phase of ERK1/2 activation, 
suggesting that cAMP is required for ERK1/2 response in the 
receptor endocytosis-dependent phase.
sAC is involved in CRH signaling in 
AtT20 corticotrophs but not in 3T3L1-
CRHR1 cells
Is sAC a specific component of CRHR1 signaling in a hip-
pocampal neuronal context, or does it have a general role in 
CRHR1 function? To answer this question, we selected the 
mouse pituitary-derived corticotroph cell line AtT20 as a sec-
ond physiologically relevant context of CRH action. In AtT20 
cells, CRHR1 (Peeters et al., 2004) and sAC (Fig. 1 A) are en-
dogenously expressed, and CRH elicits a transient increase in 
cAMP levels and activates ERK1/2 (Fig. S2, A and B).
Figure 1. Involvement of sAC in CRH-medi-
ated cAMP response. (A) sAC was detected 
by RT-PCR in total mouse brain extracts and 
different mouse cell lines. HPRT was used as 
control. (B) Depletion of sAC in HT22-CRHR1 
cells transfected with siRNA against GL3 (con-
trol) or sAC. Western blot developed with sAC 
monoclonal antibody and total ERK1/2 as a 
loading control. (C–E) Time course of FRET 
changes was measured in single HT22-CRHR1-
Epac-SH187 cells. Cells were stimulated at time 
0 with CRH (C and E) or isoproterenol (D). 
tmAC-specific (100  µM ddA) or sAC-specific 
(20 µM 2-HE) inhibitors were added 1.5 min 
after stimulation. Traces are representative of 
three independent experiments (mean ± SEM, 
20–25 cells). (E) Cells were transfected with 
50 nM siRNA against GL3 (control) or sAC 
for 72 h. Inset shows efficiency of sAC knock-
down assessed by quantitative RT-PCR normal-
ized to HPRT (mean ± SEM, n = 3). ***, P 
< 0.001 by Student’s t test. (F) Inhibition of 
cAMP response elicited by CRH or forskolin at 
the indicated concentrations of ddA or 2-HE. 
Values represent FRET change 2.5 min after 
inhibitor addition relative to absence of any 
inhibitor (mean ± SEM, 15–20 cells).
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To determine the involvement of different cAMP sources, 
we analyzed ERK1/2 activation in response to CRH, which 
is critical for Pomc expression (Kovalovsky et al., 2002) and 
is mediated by cAMP (Van Kolen et al., 2010). Using inhib-
itors, we found that tmAC-specific ddA, as well as two sAC- 
selective inhibitors, 2-HE and KH7, impaired CRH-mediated 
ERK1/2 phosphorylation (Fig. 3 A). sAC knockdown also sig-
nificantly reduced CRH-triggered pERK1/2 levels, confirming 
that sAC participates in CRHR1 signal transduction in AtT20 
cells (Fig. 3 B). In contrast, depletion of sAC had no effect on 
Figure 2. sAC-generated cAMP has a specific role in CRHR1 signaling. (A–C) pERK1/2 and total ERK1/2 were measured in HT22-CRHR1 cells stimulated 
with CRH or isoproterenol for the indicated time points. Results are expressed as the percentage of maximum pERK1/2. (A) Cells were preincubated with 
vehicle (control) or sAC-specific (7.5 µM KH7) or tmAC-specific (100 µM ddA) inhibitors (mean ± SEM, n = 4). Two-way analysis of variance followed 
by Tukey’s test: *, P < 0.05; **, P < 0.01; ***, P < 0.001 with respect to control; #, P < 0.05; ###, P < 0.01 between indicated treatments. (B) Time 
course of FRET changes was measured in single HT22-CRHR1-Epac-SH187 cells. Cells were stimulated at time 0 with CRH. When indicated, tmAC-specific 
(100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors were added. Traces are representative of three independent experiments (mean ± SEM, 20–25 
cells). (C) Cells were transfected with 50 nM siRNA against GL3 (control) or sAC for 72 h before stimulation with CRH or isoproterenol (mean ± SEM, 
n = 3). Student’s t test was performed for each time point. *, P < 0.05; ***, P < 0.001. Efficiency of sAC knockdown assessed by quantitative RT-PCR nor-
malized to HPRT is shown (mean ± SEM, n = 3). ***, P < 0.001 by Student’s t test. (D) CRH neurogenic effect in HT22-CRHR1 cells after 20-h treatment was 
evaluated in the presence of vehicle (control) or tmAC-specific (50 µM ddA) or sAC-specific (7.5 µM KH7) inhibitors. A representative photograph is shown. 
Bar, 50 µm. Neurite outgrowth was quantified by repeated-measures one-way analysis of variance followed by Tukey’s test (n = 3). ***, P < 0.001; 
**, P < 0.01 with respect to basal.
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PAC AP38-mediated ERK1/2 activation (Figs. 3 B and S2 C). 
Given that PAC AP38 also signals through a class B GPCR that 
generates a cAMP response (Fig. S2 A), these results further 
highlight that sAC is a specific component of CRHR1 signaling.
We next tested whether sAC was involved in the 
CRH-mediated activation of Pomc, a key CRH target gene in 
corticotroph cells for HPA axis activation. The transcriptional 
activity of a Pomc–Luc reporter construct (Liu et al., 1992) was 
significantly decreased in cells pretreated with sAC inhibitors 
before CRH stimulation, whereas no effects on basal activities 
were observed (Fig. 3 C). These findings are consistent with the 
participation of sAC in a second signaling scenario and suggest 
that sAC has a key role for CRHR1 action.
We used the mouse fibroblast 3T3L1 cell line stably 
expressing CRHR1 (3T3L1-CRHR1), which endogenously 
expresses sAC (Fig.  1  A), as a third cellular context to ex-
plore a role of sAC in CRHR1 signaling. Treatment with the 
cell membrane–permeable cAMP analog 8-CPT-cAMP en-
hances ERK1/2 phosphorylation in cells in which ERK1/2 
activation is dependent on increased cAMP levels. ERK1/2 
response to 8-CPT-cAMP in the three cell lines was deter-
mined (Fig. 3 D). Although CRH activated ERK1/2 and CREB 
in 3T3L1-CRHR1 cells (Fig. S2 D), pERK1/2 was not linked 
to increased cAMP levels in this system, unlike in ATt20 and 
HT22-CRHR1 cells (Fig. 3 D).
We tested the participation of sAC in 3T3L1-CRHR1 cells 
by measuring the CRH-mediated cAMP response using the 
FRET-based biosensor. CRH stimulation triggered a rapid and 
sustained increase in cAMP levels. Interestingly, whereas the 
tmAC-selective inhibitor ddA attenuated the cAMP response, 
the addition of sAC-specific inhibitor 2-HE did not have a sig-
nificant effect on the cAMP time course (Fig. 3 E). To rule out 
the possibility that this result was caused by low sAC expression 
levels, the experiment was also performed with overexpression 
of the highly active sACt isoform, with similar results (Fig. 3 F).
CRH-activated CRHR1 has been shown to trigger an in-
crease in calcium in several cellular contexts (Kovalovsky et 
al., 2002; Gutknecht et al., 2009; Bonfiglio et al., 2013). Be-
cause calcium activates sAC (Jaiswal and Conti, 2003; Carlson 
et al., 2007; Kleinboelting et al., 2014), we asked whether a 
CRHR1-dependent calcium response was present in 3T3L1-
CRHR1 cells. Using Fluo-4 calcium indicator, we verified that, 
upon CRH stimulation, there was a calcium increase that could 
be completely blocked with the extracellular calcium chelator 
EGTA (Fig. S2 E). In conclusion, despite the fact that CRH-
driven responses in 3T3L1-CRHR1 and HT22-CRHR1 cells are 
comparable in terms of cAMP (Fig. 1 C and Fig. 3, E and F) and 
calcium responses (Bonfiglio et al., 2013), sAC is not involved 
in cAMP generation in 3T3L1-CRHR1 cells. These findings 
suggest that the involvement of sAC is dependent on the cellu-
lar context and that there is a functional association between the 
sAC-generated cAMP pool and the ERK1/2 pathway.
CRH-stimulated sAC activates 
PKA and EPACs
Both PKA and EPACs (cAMP-stimulated guanine nucleotide 
exchange factors) can trigger the ERK1/2 pathway (Kawasaki 
et al., 1998). It has been shown that sAC-generated cAMP sig-
nals through PKA during capacitation in mammalian sperm 
(Wertheimer et al., 2013), during leukocyte transendothelial 
migration (Watson et al., 2015), and in H2O2-stimulated air-
way epithelia (Ivonnet et al., 2015), whereas the sAC-EPAC-
Figure 3. CRH responses in AtT20 and 
3T3L1-CRHR1 cells. (A) pERK1/2 and total 
ERK1/2 were measured in AtT20 cells prein-
cubated with vehicle (control) or tmAC-specific 
(50 µM ddA) or sAC-specific (7.5 µM KH7 or 
10  µM 2-HE) inhibitors and stimulated with 
CRH. (B) pERK1/2 and total ERK1/2 were 
measured in AtT20 cells transfected with 50 
nM siRNA against GL3 (control) or sAC and 
stimulated with CRH or PAC AP38. Results 
are expressed as the percentage of max-
imum pERK1/2 (mean ± SEM, n = 3). *, P 
< 0.05 by Student’s t test. Efficiency of sAC 
knockdown assessed by quantitative RT-PCR 
normalized to HPRT is shown (mean ± SEM, 
n = 3). ***, P < 0.001 by Student’s t test. 
(C) Response to CRH in AtT20 cells transiently 
transfected with Pomc–Luc and pretreated with 
7.5 µM KH7 or 10 µM 2-HE. Each value was 
normalized to β-Gal activity (mean ± SEM, n 
= 4 of one representative of three indepen-
dent experiments with similar results). ***, P 
< 0.001; *, P < 0.05 with respect to control 
by two-way analysis of variance followed by 
Tukey’s test. (D) pERK1/2 and total ERK1/2 
of HT22-CRHR1, AtT20, or 3T3L1-CRHR1 cells 
treated with 8-CPT-cAMP. (E,F) 3T3L1-CRHR1 
cells expressing Epac-SH187 were stimulated 
at time 0 with CRH. (F) Cells were transfected 
with sACt-HA. When indicated, 100 µM ddA 
or 20  µM 2-HE was added. Time course of 
FRET changes were measured in single cells. 
Traces are representative of three independent 
experiments (mean ± SEM, 20–30 cells).
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Rap1 axis has been associated with cell proliferation in prostate 
and breast cancer cells (Flacke et al., 2013; Appukuttan et al., 
2014; Onodera et al., 2014).
In HT22-CRHR1 cells, pharmacologic inhibition of PKA 
reduced CRH-mediated early ERK1/2 activation, without af-
fecting late time points (Fig. 4, A and B). To study PKA ac-
tivation directly, we expressed the FRET-based PKA activity 
sensor AKAR4 (Allen and Zhang, 2006; Depry et al., 2011). 
Preincubation with ddA as well as 2-HE significantly prevented 
CRH-triggered PKA activation (Fig.  4  C). Thus, cAMP gen-
erated through tmAC and sAC contributes to PKA activity in 
CRH-stimulated HT22-CRHR1 cells.
To determine the role of EPACs on CRH action, we used 
the EPAC1 and EPAC2 inhibitor ESI09 (Zhu et al., 2015) at 
its lowest effective concentration to avoid reported nonspecific 
effects (Rehmann, 2013). Preincubation with ESI09 strongly 
reduced CRH-mediated pERK1/2 at both early and late time 
points (Fig. 4 D). Genetic silencing of EPAC1 and EPAC2 and 
transfection with the dominant-negative N-EPAC also dimin-
ished ERK1/2 activation (Fig. 4, E–G). The modest impact of 
EPAC knockdown may result from incomplete protein deple-
tion. Alternatively, the stronger action of ESI09 or N-EPAC 
may result from nonspecific effects of these treatments. There-
fore, EPACs participate in the activation of ERK1/2 in response 
to CRH in the hippocampal neuronal context. Moreover, the 
involvement of EPACs in the sustained phase of ERK1/2 acti-
vation further supports that the endocytosis-dependent mecha-
nism of ERK1/2 activation requires cAMP.
In AtT20 cells, CRH-induced ERK1/2 activation was 
slightly decreased in the presence of the PKA inhibitor RpcAMPS 
(Fig. 4 H). Treatment with the EPAC inhibitor impaired pERK1/2 
in response to CRH (Fig. 4 I). Thus, in line with previous studies 
(Van Kolen et al., 2010), the main cAMP effector underlying 
CRH-mediated ERK1/2 activation in AtT20 cells is EPAC. Col-
lectively, these results indicate that sAC-generated cAMP does 
not signal preferentially through a specific cAMP effector, being 
able to activate both PKA and EPAC in response to CRH.
Endocytosis-dependent cAMP is generated 
in response to CRH
CRHR1–β-arrestins interactions are involved in CRHR1 desen-
sitization (Perry et al., 2005; Holmes et al., 2006; Oakley et al., 
2007). We have shown previously that, upon ligand stimulation, 
CRHR1 is internalized and stays in endocytic compartments 30 
min after CRH addition. We examined agonist-induced CRHR1 
internalization in HT22-CRHR1 cells. CRH activation pro-
moted a fast internalization of the receptor, with a time course 
that overlapped that of cAMP production: a significant fraction 
of CRHR1 was internalized after 5 min and remained constant 
for at least 30 min of CRH stimulation (Fig. 5 A). The fact that 
both the early and late phases of ERK1/2 activation were af-
fected when sAC activity was inhibited or silenced led us to pos-
tulate that CRHR1 endocytosis and sAC activity may be linked. 
To test this hypothesis, we used two experimental approaches to 
inhibit endocytosis and measured the time course of cAMP ac-
cumulation mediated by CRH with the FRET-based biosensor.
Figure 4. sAC effectors in HT22-CRHR1 and 
AtT20 cells. (A,B,D–F) pERK1/2 and total 
ERK1/2 were measured in HT22-CRHR1 cells 
stimulated with CRH for the indicated time 
points. (A, B, and D) Cells preincubated with 
vehicle (control), PKA inhibitors (A: 700 nM 
KT5720; B: 75 µM RpcAMPS), or EPAC-spe-
cific inhibitor (5  µM ESI09) were stimulated 
with CRH. In D, results are expressed as the 
percentage of maximum pERK1/2 after stimu-
lation under control conditions (mean ± SEM, 
n = 3). *, P < 0.05; **, P < 0.01; ***, P 
< 0.001 by Student’s t test. (C) HT22-CRHR1 
cells stably expressing AKAR4 were preincu-
bated with tmAC-specific (100  µM ddA) or 
sAC-specific (20 µM 2-HE) inhibitors and stim-
ulated with CRH at time 0. Time course of FRET 
changes was measured in single cells. Traces 
are representative of three independent ex-
periments (mean ± SEM, 20–25 cells). (E and 
F) Cells were transfected with 50 nM siRNA 
against GL3 (control), EPAC1, or EPAC2 for 
72  h before CRH stimulation. Efficiency of 
EPAC1 or EPAC2 knockdown assessed by 
quantitative RT-PCR normalized to HPRT is 
shown (mean ± SEM, n = 3). ***, P < 0.001 
by Student’s t test. (G) Cells were transfected 
with EPAC1 (control) or dominant negative 
N-EPAC 48 h before CRH stimulation. (H and 
I) pERK1/2 and total ERK1/2 were measured 
in AtT20 cells preincubated with vehicle (con-
trol), PKA inhibitor (75 µM RpcAMPS; H), or 
EPAC inhibitor (10 µM ESI09; I) and stimulated 
with CRH for the indicated times.
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First, we used a genetic approach, expressing a domi-
nant-negative mutant of dynamin (DynK44A) that is required 
for later stages of clathrin-dependent endocytosis. DynK44A 
blocked CRHR1 internalization upon ligand stimulation (Fig. 
S3, A and B) and the sustained ERK1/2 activation phase in 
HT22-CRHR1 cells (Bonfiglio et al., 2013). Cells transfected 
with DynK44A showed a diminished cAMP response com-
pared with control cells (Fig. 5 B). Next, we followed a pharma-
cologic approach using Dyngo-4a, which chemically inhibits 
dynamin’s GTPase activity, blocking endocytosis (Fig. S3, A 
and C). As in cells expressing DynK44A, the cAMP response 
to CRH was impaired by Dyngo-4a treatment, showing a profile 
similar to the one observed with DynK44A (Fig. 5 D).
The early increase of CRH-mediated cAMP accumu-
lation did not seem to be affected by dynamin-deficient mu-
tant or Dyngo-4a. The differences in the time course of the 
cAMP response when endocytosis was inhibited were signifi-
cant 3.5 min after CRH stimulation (Fig. 5, B and D), in line 
with fast CRHR1 endocytosis (Fig. 5 A; Kotowski et al., 2011; 
Bonfiglio et al., 2013). Importantly, DynK44A expression or 
Dyngo-4a treatment did not significantly affect the cAMP re-
sponse elicited by receptor-independent activation of adenylyl 
cyclases with forskolin (Fig. 5, C and E), confirming that the 
effect of endocytosis inhibition required pathway stimulation 
by the activated receptor.
Changes in the CRH-dependent calcium response cannot 
be ascribed to a decreased cAMP response in these cells be-
cause a similar calcium response was observed in both control 
and DynK44A-expressing cells (Fig. S3 D). Thus, inhibition of 
endocytosis produces a significant decrease of cellular cAMP 
accumulation mediated by CRHR1.
For the class B GPCR PTHR, PTH-triggered cAMP 
production continues after internalization by a mechanism de-
pendent on receptor interaction with β-arrestins and prolonged 
ERK1/2 signaling (Feinstein et al., 2011). We investigated 
whether activated ERK1/2 was involved in the CRH-cAMP 
response in HT22-CRHR1 cells. When cells were pretreated 
with the MEK1/2 inhibitor U0126, a complete blockage of 
CRH-activated ERK1/2 was observed (Fig. S3 E). However, 
no differences were found between control and treated cells 
in the CRH-mediated cAMP response (Fig. S3 F), indicating 
that cAMP generated by CRH-activated CRHR1 does not de-
pend on ERK1/2 activation.
sAC activity is essential for endocytosis-
dependent CRHR1 signaling
We investigated the cAMP source involved in CRHR1 signaling 
after internalization, combining ACs inhibitors with endocytosis 
blockage. HT22-CRHR1-Epac-SH187 cells transfected with an 
empty vector or DynK44A mutant (coexpressed with mCherry) 
were mixed so that both types of cells could be treated, CRH-stim-
ulated, and analyzed in the same microscope field (Fig.  6  A). 
When cells were preincubated with vehicle or the tmAC inhibitor 
ddA, cAMP levels were reduced faster in cells transfected with 
DynK44A compared with neighboring control cells. However, 
preincubation with the sAC inhibitor 2-HE led to a loss of the 
endocytosis effect on the cAMP response to CRH (Fig. 6 B). This 
result strongly suggests that the endocytosis-dependent compo-
nent of the cAMP response is largely dependent on sAC activity. 
Importantly, 2-HE did not affect CRH-activated CRHR1 endocy-
tosis, as shown by flow cytometry analysis and subcellular local-
ization of CRHR1-GFP (Fig. 6, C and D).
Figure 5. cAMP response to CRH depends on 
endocytosis. (A) Agonist-induced CRHR1 inter-
nalization was analyzed by fluorescence flow 
cytometry at the indicated time points after 
stimulation by 10 nM CRH in HT22-CRHR1 
cells. Fluorescence at time 0 was defined as 
100% (mean ± SEM, n = 4, 10,000 cells/
condition). ***, P < 0.001; **, P < 0.01 with 
respect to basal by one-way analysis of vari-
ance followed by Tukey’s test. HT22-CRHR1-
Epac-SH187 cells were stimulated at time 0 with 
CRH (B and D) or forskolin (C and E). (B and 
C) Cells were transfected with pcDNA3 (con-
trol) or DynK44A 48 h before stimulation. (D 
and E) Cells were preincubated with vehicle 
(control) or 30 µM Dyngo-4a 15 min before 
stimulation. Time course of FRET changes was 
measured in single cells (mean ± SEM, n = 
4). Student’s t test was performed for each 
time point. P values in gray; P = 0.05 is indi-
cated with a dotted line.
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The differences between CRH-elicited cAMP responses 
in the presence or absence of a functional endocytosis machin-
ery can be measured for at least 20 min (Fig. S3 G). As a con-
trol, when ddA was added after 10 min, cAMP responses were 
reduced, but the difference in cAMP levels between control and 
DynK44A cells was maintained (Fig. S6 H). This further indi-
cates that tmACs are still active but are not critical for endocy-
tosis-dependent cAMP generation.
The effect of sAC inhibition and endocytosis blockage 
on ERK1/2 activation was assessed (Fig. 6 E). As previously 
shown (Fig.  2  A), preincubation with the sAC-specific in-
hibitor KH7 diminished ERK1/2 activation at early and late 
time points, whereas the endocytosis inhibitor Dyngo-4a 
caused a significant reduction of late pERK1/2. Simultaneous 
inhibition of sAC activity and endocytosis resulted in lower 
ERK1/2 activation at the early time point compared with 
Dyngo-4a treatment alone, showing that sAC plays a role in 
the early endocytosis-independent phase. Remarkably, both 
treatments, separately or combined, reduced late pERK1/2 to 
a similar extent, suggesting that sAC activity and endocyto-
sis are involved in the same mechanism that operates at the 
second signaling phase.
CRH-triggered response depends on sAC 
modulators: calcium and bicarbonate
sAC is stimulated by calcium (Jaiswal and Conti, 2003; Carlson 
et al., 2007; Kleinboelting et al., 2014), which may regulate sAC 
activity in neurons (Wu et al., 2006; Corredor et al., 2012). In 
HT22-CRHR1 cells, CRH elevates intracellular calcium (Bon-
figlio et al., 2013). To monitor cAMP and calcium responses 
simultaneously, we used the FRET-based cAMP sensor in com-
bination with a genetically encoded red calcium indicator, REX-
GECO1 (Wu et al., 2014). CRH stimulation resulted in rapid 
and synchronized responses of both second messengers, albeit 
with different profiles: intracellular calcium increased sharply 
upon stimulation and returned to basal levels after 60 s, whereas 
cAMP levels were sustained (Fig.  7, A and B). Preincubation 
with the cell-permeable calcium chelator BAP TA-AM reduced 
pERK1/2 at both early and late time points (Fig. S4 A), showing 
that calcium is critical for the ERK1/2 response. Remarkably, the 
ERK1/2 activation profile in the presence of calcium chelators 
was reminiscent of the one silencing sAC (Fig. 2 C).
In addition to sAC, two tmACs (AC1 and AC8) are also 
positively regulated by calcium (Willoughby and Cooper, 2007). 
In accordance with our previous study that the tmAC-specific 
Figure 6. sAC is critical for endosome-gener-
ated cAMP in response to CRH. (A) Schematic 
representation of the experimental design. 
HT22-CRHR1-Epac-SH187 cells transfected with 
pcDNA3 (control) or DynK44A plus mCherry 
for 48 h were pretreated with vehicle (DMSO) 
or tmAC-specific (100 µM ddA) or sAC-specific 
(20  µM 2-HE) inhibitors and stimulated with 
10 nM CRH. (B) Time course of FRET changes 
was measured in single cells. The cAMP re-
sponse is expressed as the percentage of max-
imum FRET signal obtained in each condition 
assayed after stimulation (mean ± SEM, n = 
7). Student’s t test was performed for each time 
point. P values in gray; P = 0.05 is indicated 
with a dotted line. (C and D) Effect of 2-HE 
on agonist-induced CRHR1 internalization an-
alyzed by fluorescence flow cytometry (C) and 
cMyc-GFP-CRHR1 subcellular distribution (D). 
HT22-CRHR1 cells preincubated with vehicle 
(control) or 20 µM 2-HE were stimulated with 
10 nM CRH for the indicated times. (C) Fluo-
rescence measured at time 0 was defined as 
100% (mean ± SEM, n = 4, 10,000 cells/
condition). (D) Representative images ob-
tained for each condition. Arrowheads point 
to internalized GFP clusters. Bars, 5  µM. (E) 
pERK1/2 and total ERK1/2 were measured in 
HT22-CRHR1 cells preincubated with vehicle 
(control) or sAC-specific (7.5 µM KH7) or en-
docytosis-specific (30 µM Dyngo-4a) inhibitors 
and stimulated with CRH. Results are expressed 
as the percentage of maximum pERK1/2 
(mean ± SEM, n = 4). Two-way ANO VA fol-
lowed by Tukey’s test: *, P < 0.05; **, P < 
0.01; ***, P < 0.001 with respect to control; 
#, P < 0.05 between indicated treatments. on
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inhibitor ddA affected only the early phase of ERK1/2 activa-
tion (Bonfiglio et al., 2013), knockdown of AC1 significantly 
diminished pERK1/2 at early time points but did not alter the 
sustained phase (Fig. 7 C). We could not detect AC8 expression 
in this system or an effect on the ERK1/2 response using an 
siRNA against AC8 (Fig. S4, B and C).
If CRH-mediated calcium influx were critical for sAC 
activation, a reduced cAMP response would be expected when 
CRH-elicited calcium increase is blocked. CRH-triggered cAMP 
response was diminished to a similar extent by extracellular EGTA 
and cell-permeable BAP TA-AM calcium chelators in pretreated 
HT22-CRHR1 cells (Fig. 7 D), indicating that the cAMP response 
depends, at least partially, on a calcium-sensitive mechanism. 
Notably, the calcium response elicited by CRH was not altered in 
HT22-CRHR1 cells preincubated with ddA or 2-HE (Fig. 7 E), 
suggesting that calcium, required for sAC activity, would not de-
pend on cAMP stimulation by CRH-activated CRHR1.
Next, we examined the effect of the sAC-specific modu-
lator bicarbonate (Steegborn et al., 2005; Kleinboelting et al., 
2014) on the ERK1/2 response to CRH. Bicarbonate concen-
tration in the culture medium used to grow cells and perform 
experiments was 25  mM, which reproduces the bicarbonate 
concentration in vivo. When we stimulated HT22-CRHR1 cells 
with CRH in bicarbonate-free medium, ERK1/2 activation was 
strongly attenuated. Strikingly, the late phase of ERK1/2 activa-
tion almost disappeared (Fig. 8 A).
Pharmacologic blockage of anion exchangers with stil-
bene derivative DIDS modulated bicarbonate levels and sAC 
activity (Choi et al., 2012). Recently, DIDS has been shown to 
inhibit sAC by competition with bicarbonate (Kleinboelting et 
al., 2014). CRH-mediated pERK1/2 in the presence of DIDS 
resulted in a modest decrease of the ERK1/2 response at early 
time points and almost null ERK1/2 activation at late time 
points (Fig. 8 B). By either silencing sAC (Fig. 2 C) or block-
ing bicarbonate transport (Fig. 8 B), we found reduced CRH- 
dependent ERK1/2 activation, which provides further evidence 
for a role of bicarbonate-sensitive sAC activity in CRHR1 sig-
naling in HT22-CRHR1 cells.
Collectively, these data are consistent with a mechanism 
in which CRH-activated sAC is regulated by calcium and bicar-
bonate and support the notion of sAC activity being required in 
the late phase of ERK1/2 activation.
Figure 7. CRH-triggered calcium response 
regulates cAMP. (A and B) HT22-CRHR1 
cells cotransfected with Epac-SH187 and REX-
GECO1 were stimulated with 100 nM CRH. 
(A) Representative images for each signal. 
Bar, 5 µm. (B) Time course of FRET changes 
(black trace) or REX-GECO1 fluorescence (or-
ange trace). Data: mean ± SEM, 14 cells. (C) 
pERK1/2 and total ERK1/2 were measured 
in HT22-CRHR1 cells transfected with 50 nM 
siRNA against GL3 (control) or AC1 and stim-
ulated with CRH. Results are expressed as the 
percentage of maximum pERK1/2 after stimu-
lation under control conditions (mean ± SEM, 
n = 3). *, P < 0.05; **, P < 0.01 by Student’s 
t test. Efficiency of AC1 knockdown assessed 
by quantitative RT-PCR normalized to HPRT is 
shown (mean ± SEM, n = 3). **, P < 0.01 
by Student’s t test. (D) HT22-CRHR1-Epac-SH187 
cells preincubated with vehicle (control), 5 µM 
BAP TA-AM, or 500  µM EGTA were stimu-
lated at time 0 with CRH. Time course of FRET 
changes was measured in single cells (mean 
± SEM, n = 3). (E) Calcium response was de-
termined in HT22-CRHR1 cells pretreated with 
tmAC-specific (100  µM ddA) or sAC-specific 
(20  µM 2-HE) inhibitors, loaded with Fluo-
4-AM, and stimulated at time 0 with 100 nM 
CRH (mean ± SEM, n = 3).
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Discussion
In this study, we demonstrate that sAC is a second source of 
cAMP in CRHR1 signaling mechanisms elicited by CRH 
in two physiologically relevant contexts of CRH action. We 
show that cAMP generated by sAC contributes to the over-
all cAMP response and that it is critical for ERK1/2 activa-
tion upon CRH treatment.
Our work in the hippocampal neuronal context, HT22 
cells, also indicates that CRH-activated CRHR1 continues to 
generate cAMP from endocytic compartments, as recently 
demonstrated for several GPCRs (Irannejad and von Zastrow, 
2014; Vilardaga et al., 2014). The study of CRH-activated 
CRHR1 uncovers a previously unanticipated link between sAC 
and endosome-based GPCR signaling. These findings revise 
the canonical model in which GPCR-elicited cAMP production 
relies solely on tmACs.
A role of sAC in GPCR signaling is just beginning to 
emerge; only scarce and indirect evidence has been provided 
so far (Halm et al., 2010; Ivonnet et al., 2015). sAC is unique 
among the ACs in being activated by bicarbonate and calcium 
(Jaiswal and Conti, 2003; Han et al., 2005). Moreover, unlike 
tmACs, sAC has no membrane-spanning domains and is dis-
tributed throughout the cell. Despite growing evidence that sAC 
might be responsible for cAMP-mediated functions previously 
attributed to tmACs, little is known about the mechanisms in-
volved. Here, we identified a key role of CRHR1-induced cal-
cium for sAC activation with both PKA and EPAC effector 
proteins downstream of sAC (Fig. 8 C).
In HT22-CRHR1 cells, PKA is involved only in the early 
ERK1/2 activation phase, whereas EPAC participates in both 
phases. In the neuroendocrine cell model AtT20, ERK1/2 acti-
vation was dependent on both PKA and EPAC. Notably, cAMP 
and ERK1/2 responses to CRH are short-lived in these cells, 
resembling the acute phase of pERK1/2 in HT22-CRHR1. Al-
though our data do not rule out an endosome-based CRHR1 
signaling mechanism in AtT20 cells, which remains to be ex-
plored, they show that ERK1/2 activation requires sAC.
How is sAC physically integrated in signaling com-
plexes at specific cellular locations? Recent work describes 
a complex assembled by ezrin, an A-kinase anchoring pro-
tein that holds sAC at the plasma membrane (Watson et al., 
2015). A systematic analysis of sAC interactions will provide 
insight into specific functions of spatially restricted cAMP 
pools in cellular responses.
We show that sAC is not a general mediator of GPCRs that 
activate ERK1/2 downstream of cAMP. Alternative sources of 
cAMP involved in signaling generated by GPCRs from the en-
docytic pathway have not yet been explored. Even though sAC 
is likely to be engaged by a variety of GPCRs, its involvement 
may depend on specific features of the integral cellular response 
rather than just the mode of signaling or the cellular context.
β-Arrestins and CRHR1 internalization contribute to 
ERK1/2 activation in response to CRH, suggesting sustained 
CRHR1 signaling in endosomes (Bonfiglio et al., 2013). Our 
results show that CRHR1 endocytosis contributes to the over-
all cAMP response, in line with the emerging paradigm of en-
dosomal generation of cAMP by GPCRs, the mechanisms of 
which are just beginning to be understood. For the prototypical 
class A GPCR β-adrenergic receptor 2, the existence of a sec-
ond phase of Gs coupling from endosomes has been elegantly 
shown (Irannejad et al., 2013), whereas for the class B PTHR, 
Figure 8. CRH-elicited cAMP response de-
pends on bicarbonate. (A) HT22-CRHR1 cells 
were stimulated with CRH in HCO3−-free or 
25  mM HCO3− DMEM. (B) HT22-CRHR1 
cells preincubated with vehicle (control) or 
anion channel blocker DIDS were stimulated 
with CRH. pERK1/2 and total ERK1/2 were 
measured and expressed as the percentage 
of maximum pERK1/2 under control con-
ditions (mean ± SEM, n = 3). *, P < 0.05; 
**, P < 0.01 by Student’s t test. (C) Proposed 
model: CRH-activated CRHR1 at the plasma 
membrane generates cAMP and intracellu-
lar calcium increase. G protein–dependent 
tmACs and calcium-activated sAC contribute 
to cAMP generation, which engages PKA 
and EPAC in acute ERK1/2 activation (early 
phase). Rapid CRHR1 internalization leading 
to G protein–independent sustained ERK1/2 
activation (late phase) requires cAMP gener-
ated through sAC via EPAC.
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a prolonged Gs coupling favored by ERK1/2 and β-arrestin was 
demonstrated (Feinstein et al., 2011).
Our present findings reveal a Gs-independent mechanism 
of cAMP production with an essential role in ligand-activated 
GPCR endocytosis-mediated signaling. Although there is no 
doubt that CRHR1 activates G protein–responsive tmACs at the 
plasma membrane (Punn et al., 2012), our data support a crit-
ical contribution of G protein–independent sAC to the cAMP 
response to CRH that is linked to ERK1/2 activation in cellular 
contexts of CRHR1 signaling.
Notably, most sustained cAMP responses have been 
reported for class B GPCRs that mediate the functions of 
therapeutically relevant peptide hormones (Ferrandon et al., 
2009; Feinstein et al., 2013; Kuna et al., 2013; Merriam et 
al., 2013). Future work needs to focus on defining factors that 
modulate kinetics and spatial organization of the CRHR1- 
mediated cAMP response, which is thought to have significant 
physiological implications (Feinstein et al., 2011; Tsvetanova 
and von Zastrow, 2014). Furthermore, understanding the role 
of G protein– and endosome-dependent signaling, together 
with the identification of ligands with functional selectivity, 
may result in clinically valuable tools for pathologies involv-
ing the CRH/CRHR1 system.
Materials and methods
Cell culture and transfection
HT22-CRHR1, AtT20, and 3T3-L1-CRHR1 cell lines were cultured in 
DMEM supplemented with FBS (5% for HT22-CRHR1 and 10% for 
AtT20 and 3T3-L1-CRHR1), 2 mM l-glutamine, 100 U/ml penicillin, 
and 100 µg/ml streptomycin (Invitrogen) at 37°C in a humidified atmo-
sphere containing 5% CO2.
Plasmids were transfected using Lipofectamine and Plus Re-
agent (Invitrogen) according to the manufacturer’s instructions and 
as previously described (Bonfiglio et al., 2013). Experiments were 
performed 48 h after plasmid transfection. When single-cell measure-
ments were performed in cells transiently transfected with plasmids, 
cells were cotransfected with a fluorescent protein–expressing plasmid, 
and only fluorescent cells were used for the studies. siRNA transfection 
with Lipofectamine 2000 (Invitrogen) was performed as previously de-
scribed (Bonfiglio et al., 2013) and according to the manufacturer’s 
protocol. Experiments were performed 72 h after siRNA transfection. 
The efficiency of knockdown was assessed by quantitative RT-PCR 
normalized to HPRT, and experiments with at least 65% reduction of 
mRNA levels were considered.
Plasmids and siRNA
Plasmids were provided as follows: the mouse CRHR1 expression 
vectors c-Myc-mCRHR1 and myc-GFP-CRHR1 by J. Deussing (Max 
Planck Institute of Psychiatry, Munich, Germany); mTurquoise2- 
EPAC-cp173Venus-Venus (Epac-SH187) by K. Jalink (Netherlands Can-
cer Institute, Amsterdam, Netherlands); AKAR4 by J.  Zhang (Johns 
Hopkins University, Baltimore, MD); REX-GECO1 by R.  Campbell 
(University of Alberta, Edmonton, AB, Canada); the dynamin-K44A 
expression vector by J.  Benovic (Thomas Jefferson University, Phil-
adelphia, PA); mCherry by M.  Rossi (Instituto de Investigación en 
Biomedicina de Buenos Aires, Buenos Aires, Argentina); and EPAC1 
and N-EPAC by D.L. Altschuler (University of Pittsburgh School of 
Medicine, Pittsburgh, PA).
Rat sACfl plasmid was obtained from Addgene (pSAC5.02, 
plasmid #16077). A truncated, catalytically active form of sAC (sACt; 
Tresguerres et al., 2011) tagged with the epitope HA at the C terminus 
was generated by PCR (sACt-HA). The first 468 aa were amplified via 
PCR from sACfl using ApaI and NotI restriction sites for N and C ter-
mini, respectively, and with the C terminus of sACt and the sequence of 
the epitope (YPY DVP DYA) encoded in the reverse primer. The insert 
was ligated into pcDNA3.1(+)/Zeo (Invitrogen).
sAC knockdown was achieved using a 21-nucleotide siRNA (5′-
AAU GUA UGG GCU UCA UGGAtt-3′). siRNAs against AC1 and AC8 
were purchased from GE Healthcare as pools of four siRNAs (SMA RT 
pools; Thermo Fisher Scientific). For EPAC knockdown, the following 
siRNAs were used: EPAC1 (5′-GGU CAA UUC UGC CGG UGAUtt-3′ 
and 5′-CGA CAC CAC AGG UUG GAAAtt-3′) and EPAC2 (5′-GCU GGU 
AGA CUG GAU GAUAtt-3′ and 5′-GCU AAU CUA CCA CAC AUUUtt-3′). 
An siRNA against GL3 (5′-CUU ACG CUG AGU ACU UCG ATT-3′) was 
used as control.
Generation of stable cell lines
HT22 stable clones expressing cMyc-CRHR1 were previously de-
scribed (Bonfiglio et al., 2013). Stable clones expressing both cMyc-
CRHR1 and FRET biosensors (Epac-SH187 or AKAR4) were obtained 
by transfection of HT22-CRHR1 cells with pcDNA3.1/Zeo(+)- 
Epac-SH187 or pcDNA3.1/Zeo(+)-AKAR4 and selection with Zeocin 
(100 µg/ml; Invitrogen). 3T3-L1 stable clones expressing cMyc-
CRHR1 were obtained by transfection of pcDNA3-c-Myc-mCRHR1 
and selection with Geneticin (800 µg/ml). In both cases, after 14 d of 
antibiotic treatment, clonal colonies were isolated and subcultured.
RT-PCR and quantitative real-time PCR
Total RNA was extracted from cell lines or total mouse brain ex-
tracts using TRI reagent (MRC), and complementary DNA synthesis 
was performed using M-MLV reverse transcription in the presence 
of RNasin RNase inhibitor (Promega). PCR primers were all intron 
spanning. cDNAs were amplified using Taq DNA polymerase (Invit-
rogen). Quantitative real-time PCR was performed with SYBR Green 
I (Roche) using a CFX96 Touch Real-Time PCR Detection System. 
Relative expression was calculated for each gene by the Ct method with 
HPRT for normalization.
Sequences and expected product sizes are as follows: sAC sense 
5′-CCT GCA TCG CTG TCT GGT AT-3′, antisense 5′-GAA CTG TCG 
GGG TTC TTC GT-3′ (102 bp); AC1 sense 5′-GTG GCC AGT CGG ATG 
GAT AG-3′, antisense 5′-TTC ACG CTG ACT TTG CCT CT-3′ (119 bp); 
AC8 sense 5′-ACG TCA TCA TCT TCG CTT CCA-3′, antisense 5′-AGT 
ACT CTG GGT AGG AGC AGA-3′ (150 bp); EPAC1 sense 5′-TCT TAC 
CAG CTA GTG TTC GAGC-3′, antisense 5′-AAT GCC GAT ATA GTC 
GCA GATG-3′ (223 bp); EPAC2 sense 5′-TAA AAG GCC GTT GGA 
GCG AT-3′, antisense 5′-GCC AGG ACA GCA TAC CAG TT-3′ (195 bp); 
HPRT sense 5′-TGG GCT TAC CTC ACT GCT TTCC-3′, antisense 5′-
CCT GGT TCA TCA TCG CTA ATC ACG-3′ (139 bp); and β-actin sense 
5′-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3′, antisense 5′-
CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3′ (663 bp).
Ligand stimulation, drugs, and pharmacological inhibitors
For MAPK assays, cells were serum-starved for 6  h in OptiMEM 
before drug pretreatments or stimulation. Cells were stimulated with 
human/rat CRH (H-2435; Bachem), forskolin (13019; Cayman Chem-
ical), and 8-CPT-cAMP (F1221, Sigma-Aldrich) at the concentrations 
and time points indicated. After incubation, cells were washed with ice-
cold PBS and maintained in ice. When calcium chelators BAP TA-AM 
(B6769; Thermo Fisher Scientific), EGTA (E3889; Sigma-Aldrich), 
or pharmacologic inhibitors were used, cells were pretreated with the 
drugs or vehicle 15–30 min before stimulation. The following inhib-
itors were used: KT5720 (PKA; K3761; Sigma-Aldrich), RpcAMPS 
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(PKA; 1337; Tocris Bioscience), ddA (tmACs; 288104; EMD Milli-
pore), KH7 (sAC; 3834; Tocris Bioscience), 2-HE (sAC; 13019; Cay-
man Chemical), DIDS, anion channel blocker (D3514; Sigma-Aldrich), 
U0126 (MEK; 662005; EMD Millipore), ESI09 (EPAC1/2; SML0814; 
Sigma-Aldrich), and Dyngo-4a (dynamin; ab120689; Abcam).
For experiments testing bicarbonate dependence, bicarbon-
ate-free DMEM supplemented with 25  mM Hepes was used to pre-
pare media at 0- and 25-mM sodium bicarbonate concentrations. Each 
condition was adjusted to physiological pH 7.2 with NaOH and HCl 
and allowed to equilibrate in the incubator for additional 30 min, and 
then the pH was checked again and adjusted to 7.4. HT22-CRHR1 cells 
were serum-starved for 6 h in bicarbonate-free DMEM or 25 mM bicar-
bonate DMEM before stimulation with 10 nM CRH.
Preparation of cellular extracts and immunoblotting
After treatments, cells were washed with ice-cold PBS and lysed in 
Laemmli sample buffer. Whole-cell lysates were sonicated and heated 
to 95°C for 5 min. Samples were resolved by SDS-PAGE and trans-
ferred to 0.45-mm nitrocellulose membranes (EMD Millipore) for im-
munoblotting. Membranes were blocked in TBS–Tween 20 (0.05%) 
containing 5% milk at RT for 1 h under shaking and probed overnight 
at 4°C with the primary antibodies. The following antibodies were 
used: anti-sAC (R21; CEP Biotech), anti–c-Myc (9E10; sc-40) and 
anti–pERK1/2 (E-4; sc-7383) from Santa Cruz Biotechnology, Inc.; 
anti–total-ERK1/2 (9102; Cell Signaling Technology), anti-phos-
pho CREB (06-519; EMD Millipore), and anti–total-CREB (9104; 
Cell Signaling Technology).
Chemiluminescent signals were detected by HRP-conjugated 
secondary antibodies and enhanced chemiluminescence (SuperSignal 
West Dura; Thermo Fisher Scientific) using a GBOX Chemi XT4 (Syn-
gene). Phosphorylation of MAPK and CREB was detected with the 
Odyssey Fc Imaging System (LI-COR Biosciences), using anti-mouse-
IRDye700DX and anti-rabbit-IRDye800CW secondary antibodies 
(Rockland). Phosphorylated proteins were relativized to the total pro-
tein level, and results were expressed as the percentage of maximum 
pERK1/2 after stimulation. Immunoreactive signals were analyzed dig-
itally using ImageJ software (National Institutes of Health).
Neurite outgrowth assay
HT22-CRHR1 cells seeded at 40% density in 12-well plates were 
stimulated with 100 nM CRH in the presence of vehicle or tmAC- or 
sAC-specific inhibitors. After 20  h of treatment, cells were imaged 
under bright-field illumination using an Olympus IX81 inverted epi-
fluorescence microscope with a 20× air objective and Metamorph 
software for image acquisition. For each treatment, at least 15 random 
fields were imaged. Quantification of morphological changes was per-
formed using Simple Neurite Tracer plugin for Fiji software. Neurite 
outgrowth was determined as the ratio between the longest neurite and 
the soma diameter per cell after 20 h, measuring at least 100 cells per 
treatment. For statistical analysis, repeated-measures one-way analysis 
of variance followed by Tukey’s post hoc test (n = 3) was performed.
Single-cell intracellular calcium imaging
For experiments using ester calcium indicators, cells plated in 
glass-bottom dishes were loaded for 30–60 min in darkness with 6 µM 
Fluo-4-AM and 0.14% Pluronic F-127 (Molecular Probes) in Ringer 
buffer. Images were acquired with a Axio Observer Z1 inverted Epi-
fluorescence microscope (ZEI SS), equipped with an AxioCam HRm3 
digital CCD camera, a Stage Controller XY STEP SMC 2009 scanning 
stage, and an Incubator XLmulti S1 (D) and Heating Unit XL S1 (D) 
for live-imaging incubation. Data acquisition was controlled by Zen 
Blue 2011 software (ZEI SS), configured at a bit depth of 14 bits. Cells 
were imaged with a 20× air objective (Plan-Apochromat NA 0.8 M27) 
and illuminated using Colibri.2 470-nm LED excitation (5% power), 
with a 50-ms exposure acquired every 5  s and a 38HE Filter set for 
a duration of 10 min. When indicated, cells were preincubated with 
different reagents. Approximately 30 s after the start of the experiment, 
CRH was added to a final concentration of 100 nM. Image analysis was 
performed with Fiji by measuring calcium-dependent changes in fluo-
rescence intensity from resting levels (ΔF/F0) in 30–40 cells randomly 
selected in each experiment.
Spectral FRET and coimaging of cAMP and calcium
HT22-CRHR1, AtT20, or 3T3-CRHR1 cells expressing fluorescent 
proteins and FRET biosensors were seeded in glass-bottom dishes. Cell 
imaging was performed on an inverted LSM 710 (ZEI SS) equipped 
with an automated stage, an incubation chamber, and Definite focus 
system. Data acquisition was performed with ZEN Black 2011 soft-
ware. Images were acquired with a C-Apochromat 40×/1.2 water 
immersion and temperature-corrected objective lens at 1,024 × 1,024 
pixels, 16 bits, pixel dwell time 3.15 µs, with open pinhole (600 µm). 
The emission spectra of the fluorescent proteins Cerulean, mTur-
quoise2, Venus, and REX-GECO1 bound to calcium were determined 
using 405- or 458-nm lasers for the excitation and lambda mode for the 
detection using a 32-channel QUA SAR detector arranged with band-
width channels of 9.7 nm.
For FRET experiments, cells were illuminated with a 30-mW, 
405-nm diode laser at 2% laser power (550–650 gain) and a 405-nm 
dichroic mirror; emission was collected at 413- to 723-nm wavelengths 
every 15 s for a duration of 15 min. For coimaging cAMP and calcium 
dynamics, a 25-mW argon laser for 458-nm excitation (2.5% power, 
650 gain) and a 458-nm dichroic mirror were used; emission was col-
lected at 463- to 723-nm wavelengths every 5 s for a duration of 10 
min. The saturation level was verified for each image.
For the reference spectra and the experiments, phenol red–free 
DMEM/F12 medium supplemented with 20 mM Hepes was used, and 
imaging was performed at 37°C and 5% CO2. Approximately 2.5 min 
after the start of the experiment, CRH was added to the final concen-
tration indicated. When indicated, cells were preincubated for 15 min 
with different reagents. AC inhibitors were also added after CRH stim-
ulation to evaluate the change in the FRET time course.
For lambda FRET experiments, the linear unmixing tool of ZEN 
Black 2011 software was used to obtain an image for each fluorophore 
using the reference spectra. Image quantification was performed with 
Fiji software. After background subtraction, REX-GECO1, FRET, and 
donor intensities were measured for single cells for each time point. 
The FRET/donor ratio or REX-GECO1 intensity was calculated and 
normalized to resting levels (before stimulation).
Flow cytometry assays
For CRHR1 surface staining, HT22-CRHR1 cells on 60-mm plates 
were starved for 1 h in OptiMEM before drug pretreatments or stim-
ulation. When pharmacological inhibitors were used, cells were pre-
treated with drugs or vehicle 15–30 min before stimulation with CRH 
for the indicated concentration and time. After incubation, cells were 
washed with ice-cold PBS and harvested in 1 mM PBS-EDTA. 2.0 × 
105 cells were incubated at 4 C with 10% FBS in PBS for 1 h to reduce 
nonspecific binding. Subsequently, cells were incubated with 0.2 µg 
anti–c-Myc monoclonal antibody (Santa Cruz Biotechnology, Inc.) for 
2 h and, after washing with 1% FBS in PBS, were stained with 1.4 µg 
anti-mouse Alexa Fluor 647–conjugated secondary antibody (Thermo 
Fisher Scientific). All solutions contained 0.01% sodium azide. Con-
trols for autofluorescence, primary antibody staining on parental 
HT22 cells, and secondary antibody staining in absence of primary 
o
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antibody were performed for each experiment. Flow cytometry data 
were acquired on a FACsCAN TO II (BD). Data were analyzed using 
FlowJo software (Tree Star).
Confocal microscopy
HT22-CRHR1 cells transiently transfected with cMyc-GFP-CRHR1 
expression vector were seeded on glass coverslips. After treatment, 
cells were washed with ice-cold PBS, fixed with 4% paraformaldehyde 
in PBS, permeabilized with 0.01% Triton X-100/PBS, and stained with 
DAPI. Coverslips were washed with PBS, and cells were mounted with 
Mowiol and analyzed by confocal microscopy. Images were acquired 
on an inverted LSM 710. Data acquisition was performed with ZEN 
Black 2011 software. Images were acquired with a C-Apochromat 
63×/1.2 water immersion and temperature-corrected objective lens at 
1,024 × 1,024 pixels, 12 bits, pixel dwell time 0.52 µs, with 1 Airy 
unit. For each treatment, 15–20 individual cells were randomly selected 
and examined. No fluorescence was observed for control cells trans-
fected with an empty vector.
Competition cAMP binding assay
cAMP determination by means of competition with [3H]cAMP for 
PKA was performed as previously described (Copsel et al., 2011; Bon-
figlio et al., 2013). In brief, HT22-CRHR1 cells were pretreated for 30 
min with the indicated inhibitors, stimulated with CRH, and subjected 
to ethanol extraction followed by 15-min centrifugation at 3,000 g. Su-
pernatants were dried and resuspended in 50 mM Tris-HCl buffer, pH 
7.4.  cAMP content was determined by means of competition with 
[3H]cAMP for PKA and expressed as the percentage of stimulation rel-
ative to maximum response. The standard curve was performed using 
eight cAMP amounts ranging from 0.1 to 90 pmol. Duplicate samples 
in at least three independent experiments were analyzed.
Pomc–Luc reporter assay
Luciferase reporter assays were performed as previously described 
(Riebold et al., 2015). In brief, AtT-20 cells were seeded in 48-well 
plates and transfected with 0.3 µg Pomc–Luc and 0.1 µg RSV-Gal 
(Addgene) for normalization for 3  h using Superfect (QIA GEN) ac-
cording to the manufacturer’s instructions. Transfection mix was 
replaced with serum-free culture medium overnight. 24 h after trans-
fection, cells were pretreated with vehicle or sAC-specific inhibitors 
and stimulated with 100 nM CRH for 6 h. Cells were lysed in Passive 
Lysis Buffer (Promega), followed by measurement of reporter activity 
according to the manufacturer’s instructions (PJK GmbH). Relative 
Luc values (Luc/β-Gal) were used to normalize for transfection effi-
ciency in all experiments.
Statistics
Each experiment was performed at least three independent times. The 
results are presented as the mean ± SEM of each measurement. Com-
parisons between treatments were performed using Student’s t test and 
one- or two-way analysis of variance (GraphPad Prism) followed by 
post hoc Tukey’s test. Statistically significant differences are indicated.
Online supplemental material
Fig. S1 shows the optimization of cAMP measurements by FRET, CRH-
triggered cAMP response by competition with [3H]cAMP for PKA, 
sAC detection by Western blot, and effect of sAC-specific inhibitors in 
CRH-mediated ERK1/2 activation. Fig. S2 shows cAMP and ERK1/2 
responses triggered by CRH and PAC AP38 in AtT20 cells, ERK1/2 
and CREB activation, and calcium response to CRH in 3T3L1-CRHR1 
cells. Fig. S3 shows CRH-dependent CRHR1 endocytosis blocked by 
DynK44A and Dyngo-4a, calcium response to CRH when endocytosis 
is blocked, cAMP and ERK1/2 response in the presence of MEK1/2 
inhibitors, and sustained cAMP response in the presence and absence 
of ddA. Fig. S4 demonstrates the role of calcium in ERK1/2 activation 
in response to CRH and the expression of AC8 in HT22-CRHR1 cells. 
Online supplemental material is available at http ://www .jcb .org /cgi /
content /full /jcb .201512075 /DC1.
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